Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA)

Historical Holders from Q1 2014 to Q4 2024

Symbol
CARA on Nasdaq
CUSIP
140755109
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
54.8M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
29K
Holdings value
$9.9K
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
2
Number of sells
-62
Average Value change %
0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vifor (International) Ltd 13.5% $2.46M 7.4M Vifor (International) Ltd. Dec 17, 2024

Institutional Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q4 29K $9.9K -$3.97M $0.33 2
2024 Q3 13.5M $4.16M -$1.03M $0.31 65
2024 Q2 17.7M $4.56M +$83.6K $0.26 76
2024 Q1 2.15M $1.96M -$1.27M $0.91 19
2023 Q4 24.2M $18M -$4.89M $0.74 106
2023 Q3 26.7M $44.9M -$6.02M $1.68 116
2023 Q2 29.1M $82.2M -$18.3M $2.83 128
2023 Q1 33.5M $164M -$5.48M $4.91 160
2022 Q4 33.5M $360M -$4.58M $10.74 158
2022 Q3 34.6M $324M -$1.75M $9.36 150
2022 Q2 34.5M $315M +$22.8M $9.13 163
2022 Q1 31.7M $385M +$17.3M $12.15 174
2021 Q4 30.2M $368M +$3.28M $12.18 172
2021 Q3 29.5M $456M +$2.08M $15.45 161
2021 Q2 31.1M $444M -$29M $14.27 166
2021 Q1 29.9M $648M +$3.37M $21.71 158
2020 Q4 29.8M $451M -$10.8M $15.13 143
2020 Q3 30.6M $389M +$8.06M $12.73 149
2020 Q2 29.8M $509M +$22.2M $17.10 133
2020 Q1 32.1M $424M +$8.58M $13.21 126
2019 Q4 31.3M $504M +$4.14M $16.11 143
2019 Q3 30.3M $554M +$80.4M $18.28 137
2019 Q2 26M $559M +$83.4M $21.50 121
2019 Q1 22.3M $437M -$20.9M $19.62 127
2018 Q4 24.1M $313M -$4.83M $13.00 127
2018 Q3 23.5M $562M +$111M $23.95 139
2018 Q2 18.6M $357M +$23.5M $19.15 118
2018 Q1 17.9M $222M +$8.82M $12.38 113
2017 Q4 13.7M $167M -$24.1M $12.24 119
2017 Q3 15.5M $213M -$11.2M $13.69 114
2017 Q2 19.4M $298M +$38.2M $15.39 121
2017 Q1 17M $310M +$96.7M $18.39 107
2016 Q4 13.7M $127M +$12.7M $9.29 96
2016 Q3 11.6M $96.9M +$6.09M $8.35 78
2016 Q2 11.9M $57.3M -$25.7M $4.81 63
2016 Q1 16.2M $101M -$43.5M $6.22 89
2015 Q4 19.6M $331M +$19.9M $16.86 92
2015 Q3 18.5M $264M +$91.7M $14.29 85
2015 Q2 11.8M $143M +$15M $12.15 72
2015 Q1 11.1M $112M +$7.84M $10.05 58
2014 Q4 10.4M $104M -$3.31M $9.97 55
2014 Q3 9.72M $81.5M +$5.57M $8.39 53
2014 Q2 8.77M $149M +$1.05M $17.02 45
2014 Q1 8.62M $160M +$160M $18.61 42